Edition:
United Kingdom

Alligator Bioscience AB (ATORX.ST)

ATORX.ST on Stockholm Stock Exchange

25.00SEK
14 Dec 2018
Change (% chg)

0.30kr (+1.21%)
Prev Close
24.70kr
Open
25.00kr
Day's High
25.10kr
Day's Low
24.30kr
Volume
146,237
Avg. Vol
74,792
52-wk High
39.00kr
52-wk Low
22.10kr

Summary

Name Age Since Current Position

Peter Benson

62 2014 Chairman of the Board

Per Norlen

46 2015 Chief Executive Officer, Chief Medical Officer

Per-Olof Schrewelius

53 2016 Chief Financial Officer

Peter Ellmark

2018 Vice President Discovery

Christina Furebring

52 2001 Vice President Research and Development

Anu Balendran

2018 Vice President Business Development

Cecilia Hofvander

50 2017 Director Investor Relations & Communications

Charlotte Russell

2018 Chief Medical Officer

Carl Borrebaeck

70 2001 Director

Anders Ekblom

63 2017 Director

Ulrika Danielsson

46 2016 Independent Director

Kenth Petersson

60 2001 Independent Director

Jonas Sjogren

2015 Independent Director

Biographies

Name Description

Peter Benson

Mr. Peter Arthur Benson has been Chairman of the Board at Alligator Bioscience AB since 2014. He has been Director of the Company since 2011. He is a Swedish graduate in business administration from Lund University in Sweden and has an MA in Economics from the University of California. Peter Benson is the Managing Partner of Sunstone Capital Life Science Ventures has previously inter alia been Head of Life Science Investments for Vaekstfonden (The Danish Growth Fund) and part of Pharmacia AB’s group management. He is Board member of Arcoma Aktiebolag, Jollingham AB, Montela Aktiebolag, Opsona Therapeutics Ltd. and Sunstone Capital A/S.

Per Norlen

Dr. Per Norlen has served as Chief Executive Officer at Alligator Bioscience AB since 2015 and he has been Chief Medical Officer of the Company since September 2010. He is a registered medical doctor with a doctoral degree and specialist doctor in clinical pharmacology, and associate professor in experimental and clinical pharmacology at Lund University. Per Norlen has 25 years of research experience in pharmacology including 14 years of experience in clinical drug development with a focus on clinical phase I/II studies. He is Board member of Atlas Therapeutics AB and A Bioscience Incentive AB.

Per-Olof Schrewelius

Mr. Per-Olof Schrewelius has been Chief Financial Officer at Alligator Bioscience AB since 2016. He has a Master of Science in Business Administration and Economics from Lund University and has over 20 years of experience from different CFO and Finance Manager positions in various industries including medical technology and engineering.

Peter Ellmark

Dr. Peter Ellmark, Ph.D. has been appointed Vice President Discovery at Alligator Bioscience AB effective as of January 1, 2018. He is currently Principal Scientist at Alligator.

Christina Furebring

Dr. Christina Furebring has served as Vice President Research and Development at Alligator Bioscience AB since 2001. She is a Swedish graduate engineer and has a doctorate in immune technology from Lund University. She is also a co-founder of the FIND technology which is a cornerstone of Alligator’s technology platform. Christina Furebring has more than 20 years’ experience of working on the optimization of proteins and antibodies. She serves as Deputy Board Member in A Bioscience Incentive AB and Atlas Therapeutics AB.

Anu Balendran

Dr. Anu Balendran, Ph.D. has been appointed Vice President Business Development at Alligator Bioscience AB effective as of May 1, 2018. He previously held the role as External Innovation Director, AstraZeneca. He has a PhD in Biochemistry.

Cecilia Hofvander

Charlotte Russell

Dr. Charlotte A. Russell, M.D., Ph.D. has been appointed Chief Medical Officer at Alligator Bioscience AB effective as of January 1, 2018. Dr. Russell is a board-certified specialist in hematology and internal medicine, and will join Alligator from her role as Senior Medical Director at Genmab A/S, Denmark.

Carl Borrebaeck

Prof. Carl Borrebaeck has been Director of Alligator Bioscience AB since 2001. He is a Swedish graduate engineer from Lund University, Professor at the Department of Immunotechnology and Program Director of the CREATE Health Translational Cancer Research Centre at Lund University. Carl Borrebaeck is a co-founder of Alligator and is a board member of the Royal Swedish Academy of Engineering Sciences and former Vice-Chancellor of Lund University. He serves as Chairman of Immunovia AB (publ) and SanzaGen AB, Board member of Clinical Laserthermia Systems AB and CB Ocean Capital AB and Deputy Board member of Endo Medical AB as well as Partner of Immunova HB.

Anders Ekblom

Ulrika Danielsson

Ms. Ulrika Danielsson has been Independent Director at Alligator Bioscience AB since 2016. She has an MBA from the Gothenburg School of Business, Economics and Law at the University of Gothenburg, and has been the CFO of Castellum AB (publ) since 2014. She has worked for the Castellum Group in various senior positions since 1998 and has been a member of the corporate management of Castellum since 2006. Ulrika Danielsson is a Board member and deputy Board member respectively for a number of subsidiaries and second-tier subsidiaries within the Castellum Group.

Kenth Petersson

Mr. Kenth Petersson has been Independent Director at Alligator Bioscience AB since 2001. He has a BA from Lund University and has long experience of working in both the finance and biotechnology sectors, including as an analyst. He has been a business angel for more than 15 years and has founded a number of biotechnology companies. He serves as Chairman of AlphaBeta Aktiebolag, Biocrine AB, Biocrine Regenative Medicine Aktiebolag and Spiber Technologies AB as well as Board member of Science Pacific Aktiebolag and Genovis Aktiebolag.

Jonas Sjogren

Mr. Jonas Sjogren has been Independent Director at Alligator Bioscience AB since 2015. He is a Swedish graduate engineer in electrical engineering from Chalmers University of Technology, Registered medical doctor from the Sahlgrenska Academy (Faculty of Health Sciences at the University of Gothenburg), and has an MBA from INSEAD. He serves as Board member of Storytel AB (publ), Orbit E-sport AB, Roxette Photo NV and Omentum SA and as Deputy Board member of Execca Allocation AB.